Erasca Inc (ERAS) Stock AnalysisERASErasca Inc

Erasca, Inc. is a clinical-stage precision oncology company. The Company is focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The Company has assembled RAS/MAPK pathway-focused pipeline in the industry, consisting of modality-agnostic programs aligned with its three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes one clinical-stage program (a pan-RAF inhibitor), two IND-enabling stage programs (a pan-RAS molecular glue and a pan-KRAS inhibitor), and an additional discovery-stage program (an EGFR D2/D3 biparatopic antibody). Its lead product candidate is naporafenib, the Company initiated its SEACRAFT-2 pivotal Phase III trial for patients with NRAS-mutated (NRASm) melanoma. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Currently, Erasca Inc (ERAS) is not a good buy. The stock is trading at $13.39, which is significantly below the recent analyst price targets of $21 to $33. The RSI is at a low 27.93, indicating oversold conditions, but the company has reported substantial losses, with a net income of -183.44 million in Q1 2026. Additionally, insider selling has increased by 336.23% over the last month, raising concerns about the company's outlook.